

Evaluating Life Simple Seven's influence on brain health outcomes: The intersection of lifestyle and dementia

Diandra N Denier-Fields^{a,b}, Ronald E Gangnon^a, Leonardo A Rivera-Rivera^{c,d,e}, Tobey J Betthausen^{c,f}, Barbara B Bendlin^{c,e,f,g}, Sterling C Johnson^{c,e,f,g}, Corinne D Engelman^{a,f,g}

Affiliations:

- a) Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53726, USA
- b) Department of Nutrition Science, University of Wisconsin-Madison, Madison, WI, 53706, USA
- c) Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53792, USA
- d) Department of Medical Physics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53792, USA
- e) Geriatric Research Education and Clinical Center, Wm. S. Middleton Memorial VA Hospital, Madison, WI, 53705, USA
- f) Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53792, USA
- g) Wisconsin Alzheimer's Institute, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, WI, USA

Corresponding author:

Name: Diandra Denier-Fields

Main Address: 610 Walnut Street, 1007 WARF, Madison, WI 53726-2397

Present Address: 12812 Harney Rd, Taneytown, MD 21787

Email: ddenier@wisc.edu

Phone: (608) 563-9985

ABSTRACT

INTRODUCTION: Lifestyle factors have been studied for dementia risk, but few have comprehensively assessed both Alzheimer's disease (AD) and cerebrovascular disease (CBVD) pathologies. Our research aims to determine the relationships between lifestyle and various dementia pathologies, challenging conventional research paradigms.

METHODS: Analyzing 1231 Wisconsin Registry for Alzheimer's Prevention (WRAP) study participants, we focused on Life Simple Seven (LS7) score calculations from questionnaire data and clinical vitals. We assessed brain health indicators including CBVD, AD, and cognition.

RESULTS: Higher LS7 scores were associated with better CBVD outcomes, including lower percent white matter hyperintensities and higher cerebral blood flow, and higher Preclinical Alzheimer's Composite 3 and Delayed Recall scores. No significant associations were observed between LS7 scores and AD markers of amyloid and tau accumulation.

DISCUSSION: This study provides evidence that the beneficial effects of LS7 on cognition are primarily mediated through cerebrovascular pathways rather than direct influences on AD pathology.

1 BACKGROUND

While Alzheimer's disease (AD) is the most common form of dementia, accounting for 60-70% of cases, it has been estimated that up to half of AD cases include a vascular component, culminating in mixed pathology [1]. Based on neuropathology alone, approximately 26% of dementia cases have vascular dementia, but no AD pathology [1].

Amyloid plaques and tau tangles are markers of AD pathology that can be observed decades before a clinical diagnosis. Similarly, markers of cerebrovascular disease (CBVD) appear long before the clinical diagnosis of vascular dementia and have been linked to cognitive decline [2]. These markers include the volume of white matter hyperintensities (WMH) and reduced blood flow as measured by brain magnetic resonance imaging (MRI).

Poor cardiovascular health has been associated with cognitive decline, dementia, and WMH in late-life [3,4]. Cardiovascular disease risk can be estimated according to the American Heart Association's "Life Simple 7 ideal cardiovascular health recommendations" (LS7), which include smoking status, dietary intake, physical activity, body mass index (BMI), fasting glucose, cholesterol, and blood pressure [5].

While cardiovascular disease risk has been associated with WMH and cognitive decline, its role in AD pathology is unknown [6]. Here we aimed to test the association between the LS7 score and markers of CBVD, dementia, and AD.

2 METHODS

2.1 Study population

The Wisconsin Registry for Alzheimer's Prevention (WRAP) cohort is enriched for individuals who have a parental history of AD and may be in the preclinical stages of the disease. The study consists of a longitudinal observational cohort started in 2001, with the initial follow-up beginning in 2005 and further visits performed on a biannual basis [7]. Approximately 80% of the participants who were enrolled at baseline have remained active in the study [8]. In addition, continued recruitment and enrollment has occurred over the life of the study to increase the representation of minorities, including African Americans, Native Americans, Asians, and Hispanics. Participants were English speaking, age 40-65, and free of dementia at baseline. All participants in the study have undergone neuropsychological testing, clinical evaluation, behavioral risk factor assessment, and blood collection at each visit. A subset of participants underwent brain imaging to monitor for signs of AD and CBVD as of January 2024 and December 2023 respectively.

2.2 Cerebrovascular disease imaging

A subset of participants completed at least one MRI, which provided measurements of WMH, white matter, grey matter, cerebrospinal fluid (CSF) volume, and arterial spin labeling (ASL) perfusion. Imaging was collected using the following head coils: 48HAP, RM:Nova32channel, 8US TORSOPA, and 30AA+60PA head coils, each providing equivalent signal sensitivity. Percent WMH was calculated by dividing the total WMH volume by the total white matter, to account for varying white matter volume among participants, then multiplying by 100.

Additionally, cerebral blood flow (CBF) was measured via ASL perfusion in both gray and white matter.

2.3 Alzheimer's disease imaging

A subset of the participants completed at least one positron emission tomography (PET).

Multiple tracers were used during imaging to measure AD pathology. In this study, we were interested in the Pittsburgh compound B (PiB) tracer which assesses accumulation of beta-amyloid, and MK6240 which assesses accumulation of tau. The PiB index used in this study is an average of distribution volume ratios of cerebral amyloid within selected cortical regions of interest [9]. For tau, the Mayo Temporal Composite (MTC) used in this study is a bilateral volume-weighted composite of the parahippocampal gyrus, amygdala, temporal fusiform gyrus, inferior temporal gyrus, and the middle temporal gyrus.

2.4 Cognitive decline assessment

Cognitive composite scores (CCS), including Immediate Learning, Delayed Recall, Executive Function, and the Preclinical Alzheimer Cognitive Composite (PACC3), are widely used measures of cognitive function. Immediate Learning tests short-term memory, Delayed Recall tests long-term memory, Executive Function is a measure of cognitive processing, and PACC3 is indicative of global cognition [10]. For the Executive Function and PACC3 CCS, an alternative composite score was created by the WRAP study team used for all visits in the analyses because the Stroop test (Executive Function) and Trail-Making and Digit Symbol tests (PACC3) were no longer possible during remote visits that occurred due to the COVID-19 pandemic. Instead, the Letter Fluency ('C, F, L') test was utilized as a substitute for those tests. All composite scores

were transformed into z-scores by the WRAP study team, a commonly used technique in the field as detailed in Clark et al 2016 [10].

2.5 Life Simple Seven criteria

Height and waist and hip circumferences were measured in centimeters and weight was measured in kilograms during each participant visit. BMI was calculated as weight in kilograms divided by height in meters squared. Participants were asked to relax in a quiet room prior to blood pressure (BP) readings; their BP was taken three times per each arm and then averaged to ensure accurate readings. Blood assays included fasting plasma glucose and serum total cholesterol.

Self-reported lifestyle factors included physical activity, smoking status, and diet. Participants were asked about the following in a typical week: intensity of exercise (mild, moderate, and hard), duration of the exercise in minutes, and frequency of the exercise per week. Current smoking habits were assessed by answering “Have you ever smoked cigarettes?” and “If, yes, in the past month, have you smoked any cigarettes at all?” Participants completed a set of 15 questions about diet, corresponding to each of the Mediterranean-Dash Intervention for Neurological Delay (MIND) diet categories (**Supplemental Table 1**) [11].

2.6 Predictor variable timing and coding

2.6.1 Data collection

Upon enrollment, the WRAP study team collected information, including age, sex, smoking history, and years of education for all participants. As of 2014, at each visit, participants completed questionnaires for smoking status, physical activity, and MIND diet, and vitals were

taken, including height, weight, and BP, along with fasting blood assays for cholesterol and glucose levels.

A total of 1775 participants were included in the WRAP November 2023 data freeze. 1231 participants had all LS7 criteria at the same visit. If there were multiple visits with complete predictor data, the earliest visit was used.

2.6.2 Scoring LS7

Each predictor variable was assessed independently to provide an LS7 score of 0 (poor), 1 (intermediate), or 2 (optimal). The LS7 scoring criterion for diet was adjusted to reflect the data available in the WRAP cohort. In Sabia et al 2019 [5], authors assessed diet based on fruit and vegetable consumption, plus high fiber bread. While the WRAP cohort contains data on fruit and vegetable consumption, high fiber bread was not included in the questionnaire and whole grains were used instead. Smoking history was determined by utilizing the longitudinal data of the WRAP study. At the biannual visits, each participant provides an update on their smoking status, we were able to create a longitudinal smoking history measure that looked back at the 3 previous visits, before the other LS7 factors, and identified whether they were a never smoker, previous smoker who stopped less than or greater than 5 years ago, or current smoker. All other criteria were consistent with the LS7 scoring in Sabia et al [5] and were scored according to **Table 1**. The LS7 score had a minimum of 0 and maximum of 14.

2.7 Outcome timing

Due to the longitudinal nature of the WRAP study, outcomes were introduced over time as new imaging and diagnostic techniques became available. Cognitive testing for the four CCS started at the first follow-up visit for WRAP participants in 2005. PET imaging for AD, used in these

analyses, dated back as early as 2009. MRI imaging for CBVD, used in these analyses, started in 2019 with the introduction of newer head coils to more accurately measure both WMH and ASL perfusion. With the goal of determining the effect of the predictors on the outcomes over time, multiple analyses based on years between predictor measurement and outcome were performed: 2-4 years, 4-6 years, and 6-8 years between the primary predictor (LS7 score) and each outcome. For all outcomes, the latest available visit for each time period (e.g., 2-4 years) was used. Participant counts for those who had all LS7 predictor variables are provided in **Figure 1** for all outcomes; scans during or before December 2023 were included in this analysis. The minimum number of participants per time-point required to proceed with the analysis was n=60, allowing for 10 participants per variable in the model, and all outcomes met this requirement for each time period. We did not consider an 8-10 years time period, as it did not meet this criteria for any outcome.

2.8 Regression analysis

Generalized linear regression models were constructed using R studio package lme4 [12]. Separate models were run for each outcome: %WMH, ASL perfusion, Immediate Learning, Delayed Recall, Executive Function, PACC3, amyloid via PiB index, and tau via MK6240. All models controlled for sex, with males as the reference, and age, using age centered at 65. Models for cognitive outcomes additionally controlled for *APOE* $\epsilon 4$ count, practice effects (the number of times the participant completed cognitive testing), and education in years. *APOE* $\epsilon 4$ increases the risk of developing late onset AD, so it was included in the CCS and AD outcomes, however its contribution to CBVD is not well established and therefore it was not included in the WMH or ASL perfusion analyses [13]. The predictor variable of interest for all models was the LS7 score. The significance threshold was predetermined to be set at p-value <0.05.

3 RESULTS

3.1 Participant characteristics

The participant characteristics are based on CCS and vary slightly based on the outcome of interest where CBVD and AD imaging are subsets of the CCS group; however, the majority of the WRAP cohort participants were female (67-78%) and non-Hispanic white (91-95%; **Table 2**). The cohort is highly educated with most participants having some college education (13 or more years). Due to the nature of recruitment, the WRAP cohort has been enriched for a parental history of AD and 35-37% had at least one *APOE* ϵ 4 allele. The total LS7 score ranged from 3-14, with the mean and median being a score of 9 to 10 out of 14. This means that, in general, the cohort had a moderately healthy diet. At the 2-4 year time period between predictor and outcome, the average age of participants at the outcome measurement was 67.1 for WMH, 65.8 for ASL perfusion, 66.6 for cognitive testing, 67.4 for PiB amyloid index, and 67.2 for MK6240 tau imaging.

3.2 LS7 and CBVD

3.2.1 Percent WMH

At all time periods, an increase in age was significantly associated with a higher percent of WMH (**Figure 2a, Supplemental Table 2**). The LS7 was significant at 2-4 and 6-8 years between predictor and outcome, with an effect size from a one-unit improvement in the LS7 score similar to that of one year of age younger.

3.2.2 ASL perfusion

Cerebral blood flow was available for 404 participants that had all LS7 factors, and with the recent addition of this imaging technique, each participant is only represented in a single time-period. As expected, at all time-periods, an increase in age was associated with lower blood flow in both the white matter and gray matter (**Figure 2b-c, Supplemental Table 2**). The LS7 was significantly associated with a higher perfusion level at 6-8 years, with an effect size from a one-unit improvement in the LS7 score similar to that of 2.5-3 years of age younger; the effect sizes in the 2-4 and 4-6 year time-periods were in the same direction, but not statistically significant.

3.3 LS7 and cognition

3.3.1 PACC3 and Delayed Recall

An increase in age was significantly associated with a decrease in z-scores for PACC3 and Delayed Recall at all three time points (**Figure 3a-b, Supplemental Table 3**). A higher LS7 score was significantly associated with higher PACC3 and Delayed Recall z-scores at 2-4 years, with an effect size from a one-unit improvement in the LS7 score nearly equivalent to that of one year of age younger; the effect sizes in the 4-6 and 6-8 year time-periods were in the same direction, but not statistically significant.

3.3.2 Immediate Learning and Executive Function

An increase in age was significantly associated with a decrease in Immediate Learning and Executive Function z-scores at all three time points (**Figure 3c-d, Supplemental Table 3**). The LS7 was not significantly associated with these cognitive composite scores and any of the time points.

3.4 LS7 and AD markers

3.4.1 PiB index

The PiB index is a biomarker of amyloid accumulation as plaques in between the neurons; higher values indicate more amyloid accumulation and more AD pathology. Age and APOE ϵ 4 count were the only significant contributors to the PiB index. While the effect of age was minimal, the PiB index was higher by 0.01 per year of age at all three time points (<0.001) (**Figure 4a, Supplemental Table 4**).

3.4.2 Tau MTC

The MTC is a biomarker of tau aggregation as tau tangles in four critical regions of the brain; higher values indicate more tau aggregation and more AD pathology. Age and APOE ϵ 4 count were the only significant contributors to the MTC. While the effect of age was minimal, the MTC was higher by 0.01 per year of age at all three time points (≤ 0.002) (**Figure 4b, Supplemental Table 4**).

4 DISCUSSION

In this longitudinal study involving 1231 participants from the WRAP cohort, we investigated the relationship between cardiovascular health, as measured by the LS7 score, and various indicators of brain health, including markers of CBVD and AD pathologies, and cognitive function. We found that higher LS7 scores, indicating better cardiovascular health, were significantly associated with more favorable cerebrovascular outcomes, as indicated by lower percentages of WMH and higher CBF (ASL perfusion), 6-8 years later. Additionally, improved LS7 scores correlated with better cognitive performance in PACC3 and Delayed Recall composite scores 2-4 years later. However, no significant associations were observed between LS7 scores and AD markers such as amyloid and tau accumulation, suggesting that the beneficial effects of LS7 on cognition are primarily mediated through cerebrovascular pathways rather than direct influences on AD pathology.

Our findings align with previous research indicating that better cardiovascular health, as measured by the LS7 score, is associated with reduced risk of cerebrovascular disease and improved cognitive outcomes. Wei et al. (2022) [14] found that in the NHANES (National Health and Nutrition Examination Survey) study, higher LS7 scores were associated with higher Z scores for several cognitive function tests, including global cognition, immediate and delayed learning, Digit Symbol Substitution Test, and Animal Fluency test, supporting our findings of better cognitive performance with higher LS7 scores. Similarly, Liu et al. (2022) [15], in a cross-sectional analysis of the PRECISE (Polyvascular Evaluation for Cognitive Impairment and Vascular Events) study in China, found that lower LS7 scores were associated with higher odds of cerebral small vessel disease, including WMHs, lacunes, cerebral microbleeds, and perivascular spaces. Our study corroborates these results by showing that higher LS7 scores are

linked to lower percentages of WMHs and higher ASL perfusion, indicating healthier cerebrovascular function. While there are currently no publications focusing on the LS7 and AD imaging, a study was conducted examining the LS7 score and cerebral spinal fluid AD biomarkers. Zhao et al. (2022) [16], in the CABLE (Chinese Alzheimer's Biomarker and Lifestyle) study, reported higher (healthier) A β 42/40 ratios and lower (healthier) pTau-181 associated with an increase in the LS7 score that was specific to *APOE* ϵ 4 non-carriers. These findings are in contrast to our results of no significant associations between LS7 scores and AD imaging markers, although we did not stratify by *APOE* carrier status.

The LS7 includes seven easily accessible lifestyle metrics including diet, physical activity, smoking status, blood pressure, blood sugar, cholesterol, and BMI, which makes it ideal for implementation in a clinical setting. However, this is not the only lifestyle risk score in the current literature for dementia. Other risk scores have been developed with dementia in mind, including the CAIDE, LIBRA, ANU-ADRI, and CogDrisk scores [17-21]. Common factors among all risk scores include BMI, cholesterol, blood pressure/hypertension, blood sugar/diabetes, smoking, and physical activity. Differences are seen when it comes to the assessment of diet, focusing on either fish intake or fruits and vegetables; the inclusion of cognitive and social activities; and additional diagnoses such as depression, insomnia, and traumatic brain injury. Our study's focus on LS7 highlights the importance of cardiovascular health in reducing dementia risk, aligning with the common elements seen in these other risk scores while offering a streamlined approach to intervention. A future extension of this research includes the update from the LS7 to the American Heart Association's Life Essential Eight (LE8) that was introduced in 2022, which includes the addition of sleep and several adjustments to the LS7 factors [22].

It is well established that age is an important risk factor for CBVD, cognitive decline, and AD, where each year over the age of 65 increases the risk of declining brain health [23-25]. As expected, across all outcomes and time periods, age was significantly associated with poorer brain health. At both the 2-4 year and 6-8 year time periods there was a significant association with higher LS7 score and reduced %WMH. Interestingly, the LS7 score can partially offset the increase in risk due to age; the effect of a one-unit improvement in the LS7 score is similar to being one year younger for %WMH at the 2-4 year and 6-8 year time points. We did not see this association at the 4-6 year time period, however this may be attributed to the wide CI overlapping with 0, and a lower R^2 than the other two time periods. With CBF, we saw that a one-unit higher LS7 score was the equivalent of being 2.5 years younger for gray matter and 3 years younger for white matter, but only at 6-8 years after the initial LS7 scoring. The differences between WMH and CBF, may be attributed to the nature of the two measures. WMH typically form due to ischemia, stroke, or microbleeds, meaning that they occur at a given point in time due to a specific event or as a result of chronically reduced blood flow, whereas, CBF is more of a gradient where there can be a gradual reduction overtime, even among healthy adults [26-27].

A major strength of this study is the rich set of outcomes with relatively large sample sizes. Most researchers focus on CBVD or AD alone, and only a smaller subset includes cognition. Here we include both markers of vascular dementia and AD pathology along with cognition within the same cohort. Additionally, we allow the CBVD and AD markers to be continuous rather than categorical. It is common to place a threshold cut-off for amyloid positivity, however these are not always consistent or agreed upon across the field of AD [28-30]. With our use of %WMH,

ASL perfusion, PiB index and MK6240 as continuous measures, the results can be clearly interpreted if cut-offs change in the future.

One of the main limitations in this study was the small sample size at certain time periods. While the effect sizes often remained consistent, the results became insignificant. Another limitation was the lack of representation of different races/ethnicities. Since only 6% of the WRAP cohort self-identified as a race/ethnicity other than non-Hispanic white, we did not include race/ethnicity as a covariate in our models. However, the WRAP study is still currently recruiting additional underrepresented minorities so that future work will be more representative of the general population.

As with most longitudinal cohorts, time will aid in addressing these limitations. As WRAP continues to follow participants, the sample size will increase for the later time periods. This will provide additional visits for existing participants which will allow us to better compare our results across the time periods. We will be able to see how LS7 scores change over time and their impact on brain outcomes.

In summary, our study provides evidence in support of the role of cardiovascular health, as measured by LS7 score, on CBVD and cognition, but not AD. Our results with %WMH, CBF, Delayed Recall, and PACC3 show that a higher LS7 score, indicating better cardiovascular health, is associated with more favorable CBVD and cognition outcomes, with an effect similar to or larger than one-year younger age per each LS7 unit. This means that improvements in cardiovascular health are likely to help reduce risk of %WMH, improve cerebral blood flow, and be associated with better cognitive scores by working through the vascular pathway. Clinically, over 50% of dementia cases have a vascular component and could potentially benefit from diet and lifestyle modifications that result in improved cardiovascular health. Finally, because there

are multiple outside factors that contribute to the risk of WMH, we were able to account for 15% of the variance which makes it potentially clinically relevant. While we can't prevent people from aging, a reduction in risk of forming WMH and the ability to maintain CBF via lifestyle factors offers a significant and actionable approach that aging adults can implement at home to reduce their risk of dementia and cognitive decline.

TABLES

Table 1. Life Simple 7 definition of cardiovascular health metrics.

	Life Simple Seven Factors						
	Smoking	Diet	Physical Activity Intensity (min/week)	BMI	Fasting Glucose	Blood Cholesterol	Systolic & Diastolic Blood Pressure
Optimal (Score = 2)	Never smoked OR Stopped >5 years ago	≥2 servings of fruits and ≥2 of vegetables, PLUS ≥1 serving of whole grains	≥150 moderate OR ≥75 hard OR ≥150 moderate and hard	<25	<100 mg/dL Untreated	<200 mg/dL Untreated	SBP <120 mm Hg and DBP <80 mm Hg Untreated
Intermediate (Score = 1)	Stopped in past 5 years	≥2 servings of fruits and ≥2 of vegetables, OR ≥1 serving of whole grains	1-149 moderate OR 1-74 hard OR 1-149 moderate and hard	25 – 29.9	<100 mg/dL Treated OR 100-125 mg/dL	<200 mg/dL Treated OR 200-239 mg/dL	SBP <120 mm Hg and DBP <80 mm Hg Treated OR SBP 120-139 OR DBP 80-89 mm Hg
Poor (Score = 0)	Current Smoker	<2 servings of fruits and <2 of vegetables, PLUS no whole grains	No moderate or hard	≥30	≥126 mg/dL	≥240 mg/dL	SBP ≥140 mm Hg OR DBP ≥90 mm Hg

Scoring criteria for each participant were according to the original LS7 except diet was assessed using Fruit, Vegetable, and Whole Grain consumption. Adapted from: Sabia et al 2019 [4].

Table 2. Characteristics of the participants in each biomarker dataset at 2-4 year time period.

	WMH – MRI n = 289	CBF* – MRI n= 102	CCS – Cognitive testing n = 923	Amyloid †– PET n = 218	Tau ‡ – PET n = 213
Age	67 ± 7 50 to 81	66 ± 7 51 to 81	67 ± 7 42 to 85	67 ± 7 50 to 83	67 ± 67 51 to 81
Sex	72% Female	78% Female	68% Female	69% Female	69% Female
Race/ Ethnicity	92% NHW 6% AA 2% Other	95% NHW 4% AA 1% Other	94% NHW 4% AA 2% Other	91% NHW 6% AA 3% Other	92% NHW 5% AA 3% Other
Education§	8% ≤12 18% 13-14 23% 15-16 32% 17-18 19% ≥19	6% ≤12 26% 13-14 26% 15-16 26% 17-18 16% ≥19	10% ≤12 20% 13-14 26% 15-16 26% 17-18 18% ≥19	9% ≤12 15% 13-14 25% 15-16 33% 17-18 18% ≥19	9% ≤12 17% 13-14 22% 15-16 34% 17-18 18% ≥19
APOE ε4¶	58% 0 ε4 34% 1 ε4 3% 2 ε4 5% Unknown	54% 0 ε4 33% 1 ε4 2% 2 ε4 11% Unknown	61% 0 ε4 33% 1 ε4 3% 2 ε4 3% Unknown	58% 0 ε4 33% 1 ε4 3% 2 ε4 6% Unknown	59% 0 ε4 34% 1 ε4 3% 2 ε4 4% Unknown
LS7 Score	9 ± 2 3 to 14	10 ± 2 4 to 13	10 ± 2 3 to 14	10 ± 2 3 to 13	10 ± 2 3 to 14
Outcome	<i>Percent WMH</i> 0.46 ± 0.94 0.00 to 5.78	<i>Gray Matter</i> 45.8 ± 13.0 15.7 to 82.6 <i>White Matter</i> 30.3 ± 8.6 10.5 to 53.5	<i>Immediate Learning</i> 0.3 ± 1.1 -4.3 to 3.1 <i>Delayed Recall</i> 0.3 ± 1.1 -4.4 to 2.4 <i>Executive Function</i> 0.0 ± 1.1 -6.5 to 4.9 <i>PACC3</i> 0.1 ± 1.2 -4.4 to 5.3	<i>PIB Index</i> 1.16 ± 0.21 0.86 to 2.10	<i>MTC</i> 1.11 ± 0.22 0.79 to 2.67

*CBF as measured by and arterial spin labeling perfusion, † Amyloid measured as PIB Index; ‡Tau as measured by MK6240§ Education in years; ¶ APOE ε4 allele count. Abbreviations: WMH (white matter hyperintensities), CBF (cerebral blood flow), CCS (Cognitive Composite Score), APOE ε4 (apolipoprotein E ε4), LS7 (Life Simple Seven), PACC3 (Preclinical Alzheimer’s Composite Score, global cognition); PIB (Pittsburgh compound B), MTC (Mayo Temporal Composite)

FIGURES






Figure 1: Sample sizes for the outcomes and time period between the predictor and outcome.

1231 WRAP participants had all seven of the Life Simple Seven (LS7) criteria for at least one time period. The participants (n) were filtered by available outcome data: amyloid imaging (PIB), tau imaging (TAU), white matter hyperintensities (WMH), cerebral blood flow (CBF), cognitive composite scores (CCS). Time periods were binned based on the time between predictor and outcome: 2-4 years, 4-6 years, and 6-8 years. Participant counts vary at each time point as CCS was the only outcome that was completed by all participants. Additionally, staggered enrollment and multiple phases of outcomes contributed to the variation of representation among the imaging outcomes across time periods. Only the latest observation for each participant was counted in each time period.

2a)



b)



c)





Figure 2: Cerebrovascular Disease associations with Life Simple Seven (LS7) score.


Generalized linear model results for a) percent white matter hyperintensities (% WMH), b-c) arterial spin labeling (ASL) perfusion Age measuring cerebral blood flow in ml/min/100 g for b)

white matter and c) gray matter, after controlling for age and sex, with the LS7 score as the variable of interest and age as a reference. The sample size (n), variance (R^2), and average age are provided for each time period. The beta estimate and p-value for each significant variable is shown. Calculation for %WMH = (WMH lesion volume / total white matter volume) x 100%.


3a)



b)



c)



d)





Figure 3: Cognitive Composite Score associations with Life Simple Seven (LS7) score.

Generalized linear model results for z-scores of a) Pre-Clinical Alzheimer’s Cognitive Composite score 3 (PACC3), b) Delayed Recall, c) Immediate Learning, and d) Executive Function, after controlling for age, sex, race, *APOE* $\epsilon 4$ count, practice effects, and education in years, with the LS7 score as the variable of interest, with age as a reference. The sample size (n), variance (R^2), and average age are provided for each time period. The beta estimate and p-value for each significant variable is shown.

4a)



b)




Figure 4: Alzheimer’s Disease imaging associations with Life Simple Seven (LS7) score.

Generalized linear model results for a) PIB index (amyloid) and b) Mayo Temporal Composite (MTC) composed of a bilateral volume-weighted composite of the parahippocampal gyrus, amygdala, temporal fusiform gyrus, inferior temporal gyrus, and the middle temporal gyrus, after controlling for age, sex, and APOE ϵ 4 count with the Life Simple Seven (LS7) score as the variable of interest, with age as a reference. The sample size (n) and variance (R²) are provided for each time period. The beta estimate and p-value for each significant variable is shown.

REFERENCES

- [1] Santisteban MM, Iadecola C. Hypertension, dietary salt and cognitive impairment. *J Cereb Blood Flow Metab.* 2018;38(12):2112-2128. doi:[10.1177/0271678X18803374](https://doi.org/10.1177/0271678X18803374)
- [2] Kloppenborg RP, Nederkoorn PJ, Geerlings MI, Van Den Berg E. Presence and progression of white matter hyperintensities and cognition: A meta-analysis. *Neurology.* 2014;82(23):2127-2138. doi:[10.1212/WNL.0000000000000505](https://doi.org/10.1212/WNL.0000000000000505)
- [3] Samieri C, Perier MC, Gaye B, et al. Association of Cardiovascular Health Level in Older Age With Cognitive Decline and Incident Dementia. *JAMA.* 2018;320(7):657. doi:[10.1001/jama.2018.11499](https://doi.org/10.1001/jama.2018.11499)
- [4] Sabia S, Fayosse A, Dumurgier J, et al. Association of ideal cardiovascular health at age 50 with incidence of dementia: 25 year follow-up of Whitehall II cohort study. *BMJ.* Published online August 7, 2019;l4414. doi:[10.1136/bmj.l4414](https://doi.org/10.1136/bmj.l4414)
- [5] Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction: The American Heart Association's Strategic Impact Goal Through 2020 and Beyond. *Circulation.* 2010;121(4):586-613. doi:[10.1161/CIRCULATIONAHA.109.192703](https://doi.org/10.1161/CIRCULATIONAHA.109.192703)
- [6] Alber J, Alladi S, Bae HJ, et al. White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities. *Alzheimer's & Dementia: Translational Research & Clinical Interventions.* 2019;5(1):107-117. doi:[10.1016/j.trci.2019.02.001](https://doi.org/10.1016/j.trci.2019.02.001)
- [7] Rue AL, Hermann B, Jones JE, Johnson S, Asthana S, Sager MA. Effect of parental family history of Alzheimer's disease on serial position profiles. *Alzheimer's & Dementia.* 2008;4(4):285-290. doi:[10.1016/j.jalz.2008.03.009](https://doi.org/10.1016/j.jalz.2008.03.009)
- [8] Johnson SC, Kosciak RL, Jonaitis EM, et al. The Wisconsin Registry for Alzheimer's Prevention: A review of findings and current directions. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring.* 2018;10(1):130-142. doi:[10.1016/j.dadm.2017.11.007](https://doi.org/10.1016/j.dadm.2017.11.007)
- [9] Reed BR, Marchant NL, Jagust WJ, DeCarli CC, Mack W, Chui HC. Coronary risk correlates with cerebral amyloid deposition. *Neurobiology of Aging.* 2012;33(9):1979-1987. doi:[10.1016/j.neurobiolaging.2011.10.002](https://doi.org/10.1016/j.neurobiolaging.2011.10.002)
- [10] Clark LR, Racine AM, Kosciak RL, et al. Beta-amyloid and cognitive decline in late middle age: Findings from the Wisconsin Registry for Alzheimer's Prevention study. *Alzheimer's & Dementia.* 2016;12(7):805-814. doi:[10.1016/j.jalz.2015.12.009](https://doi.org/10.1016/j.jalz.2015.12.009)
- [11] Morris MC, Tangney CC, Wang Y, et al. MIND diet slows cognitive decline with aging. *Alzheimer's & Dementia.* 2015;11(9):1015-1022. doi:[10.1016/j.jalz.2015.04.011](https://doi.org/10.1016/j.jalz.2015.04.011)
- [12] Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. *Journal of Statistical Software.* 2015; 67(1). <https://doi.org/10.18637/jss.v067.i01>

- [13] Noguchi S, Murakami K, Yamada N, Payami H, Kaye J, Heston LL, Bird TD, & Schellenberg GD. Apolipoprotein E genotype and Alzheimer's disease. *The Lancet*. 1993;342(8873): 737–738. [https://doi.org/10.1016/0140-6736\(93\)91728-5](https://doi.org/10.1016/0140-6736(93)91728-5)
- [14] Wei J, Wang L, Kulshreshtha A, Xu H. Adherence to Life's Simple 7 and Cognitive Function Among Older Adults: The National Health and Nutrition Examination Survey 2011 to 2014. *JAHA*. 2022;11(6):e022959. doi:[10.1161/JAHA.121.022959](https://doi.org/10.1161/JAHA.121.022959)
- [15] Liu D, Cai X, Yang Y, et al. Associations of Life's Simple 7 With Cerebral Small Vessel Disease. *Stroke*. 2022;53(9):2859-2867. doi:[10.1161/STROKEAHA.122.038838](https://doi.org/10.1161/STROKEAHA.122.038838)
- [16] Zhao YL, Ou YN, Ma YH, et al. Association between Life's Simple 7 and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: the CABLE study. *Alz Res Therapy*. 2022;14(1):74. doi:[10.1186/s13195-022-01019-2](https://doi.org/10.1186/s13195-022-01019-2)
- [17] Huque MH, Kootar S, Eramudugolla R, et al. CogDrisk, ANU-ADRI, CAIDE, and LIBRA Risk Scores for Estimating Dementia Risk. *JAMA Netw Open*. 2023;6(8):e2331460. doi:[10.1001/jamanetworkopen.2023.31460](https://doi.org/10.1001/jamanetworkopen.2023.31460)
- [18] Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. *The Lancet Neurology*. 2006;5(9):735-741. doi:[10.1016/S1474-4422\(06\)70537-3](https://doi.org/10.1016/S1474-4422(06)70537-3)
- [19] Schiepers OJG, Köhler S, Deckers K, et al. Lifestyle for Brain Health (LIBRA): a new model for dementia prevention. *Int J Geriatr Psychiatry*. 2018;33(1):167-175. doi:[10.1002/gps.4700](https://doi.org/10.1002/gps.4700)
- [20] Anstey KJ, Cherbuin N, Herath PM. Development of a New Method for Assessing Global Risk of Alzheimer's Disease for Use in Population Health Approaches to Prevention. *Prev Sci*. 2013;14(4):411-421. doi:[10.1007/s11121-012-0313-2](https://doi.org/10.1007/s11121-012-0313-2)
- [21] Anstey KJ, Kootar S, Huque MH, Eramudugolla R, Peters R. Development of the CogDrisk tool to assess risk factors for dementia. *Alz & Dem Diag Ass; Dis Mo*. 2022;14(1):e12336. doi:[10.1002/dad2.12336](https://doi.org/10.1002/dad2.12336)
- [22] Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life's Essential 8: Updating and Enhancing the American Heart Association's Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association. *Circulation*. 2022;146(5). doi:[10.1161/CIR.0000000000001078](https://doi.org/10.1161/CIR.0000000000001078)
- [23] Breijyeh Z, Karaman R. Comprehensive Review on Alzheimer's Disease: Causes and Treatment. *Molecules*. 2020;25(24):5789. doi:[10.3390/molecules25245789](https://doi.org/10.3390/molecules25245789)
- [24] Deary IJ, Corley J, Gow AJ, et al. Age-associated cognitive decline. *British Medical Bulletin*. 2009;92(1):135-152. doi:[10.1093/bmb/ldp033](https://doi.org/10.1093/bmb/ldp033)
- [25] De Silva TM, Faraci FM. Contributions of Aging to Cerebral Small Vessel Disease. *Annu Rev Physiol*. 2020;82(1):275-295. doi:[10.1146/annurev-physiol-021119-034338](https://doi.org/10.1146/annurev-physiol-021119-034338)

- [26] Li Q, Yang Y, Reis C, et al. Cerebral Small Vessel Disease. *Cell Transplant*. 2018;27(12):1711-1722. doi:[10.1177/0963689718795148](https://doi.org/10.1177/0963689718795148)
- [27] Merino JG. White Matter Hyperintensities on Magnetic Resonance Imaging: What Is a Clinician to Do? *Mayo Clinic Proceedings*. 2019;94(3):380-382. doi:[10.1016/j.mayocp.2019.01.016](https://doi.org/10.1016/j.mayocp.2019.01.016)
- [28] For the Alzheimer's Disease Neuroimaging Initiative, Royse SK, Minhas DS, et al. Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. *Alz Res Therapy*. 2021;13(1):99. doi:[10.1186/s13195-021-00836-1](https://doi.org/10.1186/s13195-021-00836-1)
- [29] Pemberton HG, Collij LE, Heeman F, et al. Quantification of amyloid PET for future clinical use: a state-of-the-art review. *Eur J Nucl Med Mol Imaging*. 2022;49(10):3508-3528. doi:[10.1007/s00259-022-05784-y](https://doi.org/10.1007/s00259-022-05784-y)
- [30] Haller S, Montandon ML, Lilja J, et al. PET amyloid in normal aging: direct comparison of visual and automatic processing methods. *Sci Rep*. 2020;10(1):16665. doi:[10.1038/s41598-020-73673-1](https://doi.org/10.1038/s41598-020-73673-1)

ACKNOWLEDGEMENTS

The authors especially thank the WRAP participants and staff for their contributions to the studies. Without their efforts, this research would not be possible.

CONFLICTS

The authors report no conflicts of interest.

FUNDING

This study was supported by the National Institutes of Health (NIH) grants [R01AG27161] (Wisconsin Registry for Alzheimer Prevention: Biomarkers of Preclinical AD) and [R01AG054047] (Genomic and Metabolomic Data Integration in a Longitudinal Cohort at Risk for Alzheimer's Disease). Computational resources were supported by core grants to the Center for Demography and Ecology [P2CHD047873] and the Center for Demography of Health and Aging [P30AG017266].

CONSENT & ETHICS

All participants provided signed informed consent before participation. All ethical guidelines were met, and IRB approvals have been obtained.

KEYWORDS

White matter hyperintensities, Arterial spin labeling (ASL) perfusion, Cognition, Alzheimer's disease, Amyloid imaging, Tau imaging, Life Simple Seven score, Longitudinal